Tesamorelin Uses: What It Does, Who It's For, and How It's Used

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release more growth hormone, which in turn raises IGF-1. Its only FDA-approved use is reducing excess visceral abdominal fat in adults living with HIV-associated lipodystrophy, sold as Egrifta and Egrifta SV. Every other claim you see online is investigational or off-label.

The FDA-Approved Use: HIV-Associated Lipodystrophy

Lipodystrophy is abnormal fat redistribution that can develop in people on long-term antiretroviral therapy. In that group, tesamorelin shrinks deep abdominal fat without surgery. Regulators reviewed, tested, and approved exactly that use.

Two phase 3 trials lasting 26 weeks showed roughly a 15% to 18% reduction in visceral adipose tissue versus placebo, measured by CT scan. Trunk fat also dropped, and some participants saw better triglyceride and cholesterol numbers. Dosing was a single daily injection.

Key points from the approved label:

• Dose: 1.4 mg or 2 mg subcutaneous injection once daily, depending on formulation
• Population: adults with HIV and excess visceral abdominal fat
• Monitoring: IGF-1, blood glucose, and injection-site checks
• Not approved for: general weight loss, cosmetic fat reduction, or athletic performance

This is a prescription drug, and it should be managed by an endocrinologist or HIV specialist who can account for antiretroviral regimens and pituitary function.

Investigational Uses Researchers Have Studied

Investigators have tested tesamorelin in several other conditions, mostly in small or short trials. The results are interesting but not strong enough to support routine clinical use today.

• Mild cognitive impairment: A randomized trial in older adults suggested modest gains in executive function, though the sample was small and follow-up short.
• Nonalcoholic fatty liver disease: Studies among people with HIV found reduced liver fat and lower liver enzyme markers.
• Body composition: Some data point to small increases in lean mass alongside fat loss.
• Cardiometabolic markers: Research has examined C-reactive protein, carotid intima-media thickness, and insulin sensitivity.

So what does tesamorelin do Outside of HIV care? Right now, the honest answer is: not enough to be called a treatment. People outside HIV care who ask about sermorelin vs tesamorelin are usually comparing gentler GHRH options.

Off-Label and Fitness Use: What Is Tesamorelin Good For?

In fitness and peptide circles, the compound is sold as a fat-loss tool, especially for stubborn abdominal fat. Users often inject at night to mimic the body's natural growth hormone pulse. Reported experiences vary widely, and the strongest published evidence for real fat reduction still comes from HIV cohorts.

Forum write-ups, frequently searched as tesamorelin reddit before and after, are anecdotal and cannot be verified. Buying research-grade peptide from a gray-market seller also means no purity testing, no dose accuracy, and no medical supervision.

Tesamorelin Use and Dosing: How It's Typically Taken

Tesamorelin ships as a powder that is reconstituted with bacteriostatic water and injected subcutaneously. Clinical protocols use once-daily dosing, usually in the evening, with injection sites rotated between the abdomen, thigh, and upper arm.

Setting	Typical dose	Duration studied
FDA-approved HIV lipodystrophy	1.4 mg or 2 mg daily	26 weeks and longer
Off-label fat loss	1 mg to 2 mg daily	8 to 16 weeks per cycle
Cognitive impairment research	1 mg daily	20 weeks

Cycling is common off-label, often with four or more weeks off between blocks. Stacking is also common, and people who read about aod 9604 with tesamorelin are usually evaluating a two-peptide fat-loss approach. Blends sold under tesamorelin aod9604 cjc1295 ipamorelin 12mg blend dosage make individual dose tracking harder and safety far more difficult to judge.

Side Effects and Safety Considerations

Common side effects in trials included injection-site reactions, joint pain, muscle aches, swelling in the hands and feet, and numbness or tingling from carpal tunnel compression. Most were mild to moderate and eased after stopping treatment.

Because tesamorelin raises growth hormone and IGF-1, it can affect blood sugar and may stimulate growth of hormone-sensitive tissue. It is contraindicated during pregnancy, with active cancer, and in people with pituitary tumors or a disrupted hypothalamic-pituitary axis.

Anyone using tesamorelin needs periodic monitoring:

• IGF-1 levels, to avoid supraphysiologic exposure
• Fasting glucose and HbA1c
• Injection-site review and symptom check

Tesamorelin is a prescription medication, and off-label use belongs under a clinician familiar with growth hormone secretagogues. Talk to a healthcare professional before starting any peptide.

How Tesamorelin Compares With Related Peptides

It helps to see where this compound sits among the peptides people discuss together. A full breakdown appears under tesamorelin vs sermorelin vs cjc-1295.

Peptide	Class	Typical dose	Primary effect	FDA status
Tesamorelin	GHRH analog	1-2 mg daily	Visceral fat reduction	Approved for HIV lipodystrophy
Sermorelin	GHRH analog	200-500 mcg daily	Gentle GH and IGF-1 rise	Not approved
CJC-1295	GHRH analog	1-2 mg weekly	Extended GH pulse	Not approved
Ipamorelin	Ghrelin mimetic	100-300 mcg daily	Selective GH release	Not approved

Tesamorelin is not the same category as every peptide making headlines. For example, elamipretide uses center on rare mitochondrial disease, not body composition. Mixing classes and assuming the effects stack cleanly is a common and costly mistake.

The Bottom Line

Tesamorelin has one proven, approved job: cutting visceral belly fat in adults with HIV-associated lipodystrophy. Tesamorelin is not FDA-approved for general weight loss, cosmetic fat reduction, or sports performance. Everything else remains experimental, and self-directed use carries real risks around blood sugar, IGF-1, and hormone-sensitive tissue.

RELATED PEPTIDE TOPICTesamorelin research

COMMON QUESTIONS

Frequently Asked Questions

What is tesamorelin used for?

Tesamorelin is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, sold under the brand names Egrifta and Egrifta SV. Researchers have also studied it for fatty liver disease, mild cognitive impairment, and body composition, but those uses are not approved. It is not a general weight-loss drug.

How long do you use tesamorelin?

The pivotal trials ran 26 weeks, and the approved label supports ongoing use with monitoring. Off-label users often cycle it for 8 to 16 weeks followed by a break of at least four weeks. IGF-1, fasting glucose, and HbA1c should be checked periodically while using it.

Is tesamorelin the same as HGH?

No. Tesamorelin is a growth hormone-releasing hormone analog, which means it stimulates your own pituitary gland to release growth hormone rather than supplying growth hormone directly. It raises GH and IGF-1, but the rise follows your body's own signaling. That also means it can be suppressed or blunted by pituitary problems.